NCT00927459View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

PHASE1TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions
Hypercholesterolemia
Interventions
DRUG

PRO-040201

Single dose IV infusion

DRUG

Placebo

placebo

Trial Locations (1)

45212

Medpace Clinical Pharmacology Unit, Cincinnati

Sponsors
All Listed Sponsors
lead

Arbutus Biopharma Corporation

INDUSTRY

NCT00927459 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol | Biotech Hunter | Biotech Hunter